HER2 Breast Cancer
HER2 Breast Cancer
Advertisement
Rupert Bartsch, MDHER2 Breast Cancer | June 5, 2025
HER3-DXd shows promise for CNS metastases in breast and lung cancer in the TUXEDO-3 trial, including patients with LMD.
Maryam Lustberg, MD, MPHHER2 Breast Cancer | June 4, 2025
Dr. Lustberg discusses DESTINY-Breast09 and the potential shift to T-DXd + pertuzumab in HER2+ mBC first-line treatment.
Stephanie L. Graff, MDHER2 Breast Cancer | June 4, 2025
Stephanie Graff, MD, reviews top ASCO25 breast cancer trials, including ASCENT-04, DESTINY-Breast09, and SERENA-6.
William J. Gradishar, MDHER2 Breast Cancer | June 5, 2025
Dr. Gradishar discusses how tolerability, toxicity, and NCCN guidelines shape HER2+ breast cancer treatment decisions.
William J. Gradishar, MDHER2 Breast Cancer | June 5, 2025
Dr. William Gradishar discusses treatment sequencing strategies for HER2+ metastatic breast cancer at ASCO 2025.
Yvette C. TerrieHER2 Breast Cancer | June 3, 2025
T-DXd plus pertuzumab significantly improves PFS vs THP in HER2+ mBC, per interim results from DESTINY-Breast09.
Yvette C. TerrieHER2 Breast Cancer | June 3, 2025
THP delivers similar pCR and better tolerability than TCbHP for HER2+ early breast cancer, per phase 3 neoCARHP trial.
Yvette C. TerrieHER2 Breast Cancer | May 31, 2025
T-DXd improves PFS and cORR over chemo in HER2-low/ultralow HR+ mBC, regardless of PI3K, ESR1, or BRCA1/2 mutations.
Yvette C. TerrieHER2 Breast Cancer | May 31, 2025
T-DXd rechallenge after grade 1 ILD showed high success and prolonged benefit, with low recurrence and no grade 5 events.
Lauren Dembeck, PhDHER2 Breast Cancer | May 31, 2025
Trastuzumab rezetecan shows strong intracranial activity in HER2+ breast cancer with brain metastases in REIN trial.
Brandon TwyfordHER2 Breast Cancer | May 16, 2025
Zanidatamab plus chemo showed promising responses in HER2+ and HER2-low mBC, with durable activity in a phase I trial.
Katie KoskoHER2 Breast Cancer | May 12, 2025
Higher fat mass and lower fat density linked to increased T-DXd dose reductions and toxicity in metastatic breast cancer.
Katie KoskoHER2 Breast Cancer | May 12, 2025
Pembrolizumab plus dual HER2 blockade may offer a chemo-free option for early HER2+ breast cancer, phase 2 data suggest.
Brandon TwyfordHER2 Breast Cancer | May 7, 2025
Enhertu plus THP improved pCR over standard chemo in high-risk HER2+ early breast cancer, DESTINY-Breast11 shows.
David Winchester, MDBreast Cancer News | May 10, 2025
New staging model links treatment response to survival, refining breast cancer prognosis after neoadjuvant chemotherapy.
David Winchester, MDBreast Cancer News | May 5, 2025
A new AJCC model refines breast cancer staging after neoadjuvant chemo, filling a key gap in patient prognostication.
Hatem Soliman, MDHER2 Breast Cancer | April 29, 2025
Dr. Soliman explores dendritic cell vaccines to boost immunity and cut chemo toxicity in early HER2-positive breast cancer.
Hatem Soliman, MDHER2 Breast Cancer | April 29, 2025
Pilot study shows HER2-targeted dendritic cell vaccines may enhance immune response in early HER2-positive breast cancer.
Sara Nunnery, MD, MSCIHER2 Breast Cancer | May 1, 2025
Dr. Nunnery weighs IV Enhertu vs oral chemo, highlighting how patient goals and QoL shape treatment decisions.
Sara Nunnery, MD, MSCIHER2 Breast Cancer | May 6, 2025
Dr. Nunnery discusses HER2-low and ultralow testing and Enhertu’s role after DESTINY-Breast06 in metastatic breast cancer.
Advertisement